Tecnologie

 

ENTEROSOMA

MI2013A000576 

THE MAJOR CHALLENGE IN DEVELOPING A PRODUCT:
ACTIVE INGREDIENTS SOLUBILITY

Most of vegetal or synthetic small molecules are characterized by a high hydrophobicity, which causes poor affinity for biological membranes and insufficient bioavailability. When molecules are not able to solubilize, they are not absorbed by the systemic circulation and do not exert their activity. The current legislation requires only to verify that the substances contained in food supplements are not harmful for human beings when taken daily, and that the dosages (NRV and RDAs) are compatible with the aim of the product; nevertheless, legislation do not take into consideration whether these substances are properly delivered and therefore effective, or not.

OUR SOLUTION IS

A PATENTED TECHNOLOGICAL SYSTEM THAT HAS BEEN CREATED TO IMPROVE THE ABSORPTION OF SOME SUBSTANCES THROUGH THE INTESTINAL TRACT

THE TECHNOLOGY BEHIND ENTEROSOMA

Enterosoma technology is able to bypass the intestinal physiological barriers that impede the absorption, which are:

  • THICKNESS OF MUCOUS SECRETIONS
  • CYTOCHROMES ACTIVITY
  • PG-P PUMP ACTION
  • PROTEOLYTIC HYDROLYSIS
  • LOW TRANSMURAL FLUX BY TIGHT JUNCTIONS

 

Thanks to the innovative pool of excipients with cationized Chitosan, Enterosoma is able to temporarily loosen the tight junctions so that the active ingredient can reach the systemic circulation.

In fig. A standard condition.
In fig. B the action of Enterosoma technology on tight junctions
can be clearly observed.

PHARMACEUTICAL FORM

GASTRO-RESISTANT TABLET

 

Thanks to this pharmaceutical form, Enterosoma is able to pass through the stomach unaltered and to reach the intestine, where it releases the active ingredients, whose absorption is promoted by the patented excipients pool.

EXPERIMENTAL DATA

PHARMACOKINETIC STUDY IN VITRO ON CURCUMIN ABSORPTION

 

CLINICAL STUDY ON BERBERIN ABSORPTION

MAIN ADVANTAGES